Veraxa Biotech Holding AG (VRXA) Comparison with companies in other sectors?

Veraxa Biotech Holding AG has a share price of 136.32M. You can analyze Veraxa Biotech Holding AG (VRXA) competitors across different market sectors through stock heatmaps.

What are VRXA's NET and operating margins?

Veraxa Biotech Holding AG (VRXA) operating margin is around N/A, and net profit margin is approximately N/A as of the latest reports.

In what way does VRXA's earnings per share (EPS) trend reflect its financial momentum?

Veraxa Biotech Holding AG (VRXA) EPS is -0.51 (If EPS value is positive, then "signals consistent profit growth" if Negative then "signals consistent loss"). This metric is also critical in assessing valuation metrics like the P/E ratio for Veraxa Biotech Holding AG is -8.78, and the company's ability to reinvest or distribute profits.

What does a high ROE mean for Veraxa Biotech Holding AG?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Veraxa Biotech Holding AG like P/E which is N/A, P/B which is N/A, and PEG which is N/A. Compare them with sector averages to evaluate if the stock is priced fairly.

Veraxa Biotech Holding AG Fundamental Analysis

VRXA●NASDAQ

HealthcareBiotechnology

$4.48

$1.38(23.55%)

U.S. Market opens in 44h 9m

Veraxa Biotech Holding AG Fundamental Analysis

Veraxa Biotech Holding AG (VRXA) shows weak financial fundamentals with a PE ratio of -8.78, profit margin of N/A, and ROE of N/A. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

No significant strengths identified.

Areas of Concern

No major concerns flagged.

We analyze VRXA's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 0.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

0.0/100

We analyze VRXA's fundamental strength across five key dimensions:

Efficiency Score

Weak

VRXA struggles to generate sufficient returns from assets.

ROA > 10%

N/A

Valuation Score

Moderate

VRXA shows balanced valuation metrics.

PE < 25

-8.78

PEG Ratio < 2

N/A

Growth Score

Weak

VRXA faces weak or negative growth trends.

Revenue Growth > 5%

N/A

EPS Growth > 10%

N/A

Financial Health Score

Weak

VRXA carries high financial risk with limited liquidity.

Debt/Equity < 1

N/A

Current Ratio > 1

N/A

Profitability Score

Weak

VRXA struggles to sustain strong margins.

ROE > 15%

N/A

Net Margin ≥ 15%

N/A

Positive Free Cash Flow

N/A

Key Financial Metrics

Is VRXA Expensive or Cheap?

P/E Ratio

VRXA trades at -8.78 times earnings. This suggests potential undervaluation.

-8.78

How Well Does VRXA Make Money?

No data available.

Following the Money - Real Cash Generation

No data available.

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

N/A

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

N/A

vs 25 benchmark

P/B Ratio

Price to book value ratio

N/A

vs 25 benchmark

P/S Ratio

Price to sales ratio

N/A

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

N/A

vs 25 benchmark

Current Ratio

Current assets to current liabilities

N/A

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

N/A

vs 25 benchmark

ROA

Return on assets percentage

N/A

vs 25 benchmark

ROCE

Return on capital employed

N/A

vs 25 benchmark

How VRXA Stacks Against Its Sector Peers

Metric	VRXA Value	Sector Average	Performance
P/E Ratio	N/A	33.74	N/A
ROE	N/A	404.00%	N/A
Net Margin	N/A	-40219.00% (disorted)	N/A
Debt/Equity	N/A	0.81	N/A
Current Ratio	N/A	5.53	N/A
ROA	N/A	-281.00% (disorted)	N/A

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Veraxa Biotech Holding AG's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Veraxa Biotech Holding AG Fundamental Analysis

Key Strengths

Areas of Concern

Fundamental Health Score

Efficiency Score

Valuation Score

Growth Score

Financial Health Score

Profitability Score

Key Financial Metrics

Is VRXA Expensive or Cheap?

How Well Does VRXA Make Money?

Following the Money - Real Cash Generation

Financial Ratios Analysis

Valuation Ratios

Financial Health

Efficiency Ratios

How VRXA Stacks Against Its Sector Peers

Historical Growth Performance

5-Year Growth Trajectory

Fundamental Analysis FAQ

Veraxa Biotech Holding AG (VRXA) Comparison with companies in other sectors?

What are VRXA's NET and operating margins?

In what way does VRXA's earnings per share (EPS) trend reflect its financial momentum?

What does a high ROE mean for Veraxa Biotech Holding AG?

How do I know if AAPL is overvalued or undervalued?